KDM1A microenvironment, its oncogenic potential, and therapeutic significance

被引:0
|
作者
Tayaba Ismail
Hyun-Kyung Lee
Chowon Kim
Taejoon Kwon
Tae Joo Park
Hyun-Shik Lee
机构
[1] Kyungpook National University,KNU
[2] Ulsan National Institute of Science and Technology (UNIST),Center for Nonlinear Dynamics, CMRI, School of Life Sciences, BK21 Plus KNU Creative BioResearch Group, College of Natural Sciences
来源
关键词
Histone demethylation; Carcinogenesis; Acute myeloid leukemia; KDM1A; TLL;
D O I
暂无
中图分类号
学科分类号
摘要
The lysine-specific histone demethylase 1A (KDM1A) was the first demethylase to challenge the concept of the irreversible nature of methylation marks. KDM1A, containing a flavin adenine dinucleotide (FAD)-dependent amine oxidase domain, demethylates histone 3 lysine 4 and histone 3 lysine 9 (H3K4me1/2 and H3K9me1/2). It has emerged as an epigenetic developmental regulator and was shown to be involved in carcinogenesis. The functional diversity of KDM1A originates from its complex structure and interactions with transcription factors, promoters, enhancers, oncoproteins, and tumor-associated genes (tumor suppressors and activators). In this review, we discuss the microenvironment of KDM1A in cancer progression that enables this protein to activate or repress target gene expression, thus making it an important epigenetic modifier that regulates the growth and differentiation potential of cells. A detailed analysis of the mechanisms underlying the interactions between KDM1A and the associated complexes will help to improve our understanding of epigenetic regulation, which may enable the discovery of more effective anticancer drugs.
引用
收藏
相关论文
共 50 条
  • [1] KDM1A microenvironment, its oncogenic potential, and therapeutic significance
    Ismail, Tayaba
    Lee, Hyun-Kyung
    Kim, Chowon
    Kwon, Taejoon
    Park, Tae Joo
    Lee, Hyun-Shik
    EPIGENETICS & CHROMATIN, 2018, 11
  • [2] Therapeutic potential of targeting LSD1/KDM1A in cancers
    Zhang, Xiangyu
    Wang, Xinran
    Wu, Tianxiao
    Yin, Wenbo
    Yan, Jiangkun
    Sun, Yixiang
    Zhao, Dongmei
    PHARMACOLOGICAL RESEARCH, 2022, 175
  • [3] KDM1A Identified as a Potential Oncogenic Driver and Prognostic Biomarker via Multi-Omics Analysis
    Li, Lingyue
    Wang, Yiyu
    Mou, Yuan
    Wu, Hao
    Qin, Ye
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2021, 2021
  • [4] The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
    Harris, William J.
    Huang, Xu
    Lynch, James T.
    Spencer, Gary J.
    Hitchin, James R.
    Li, Yaoyong
    Ciceri, Filippo
    Blaser, Julian G.
    Greystoke, Brigit F.
    Jordan, Allan M.
    Miller, Crispin J.
    Ogilvie, Donald J.
    Somervaille, Tim C. P.
    CANCER CELL, 2012, 21 (04) : 473 - 487
  • [5] Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma
    Pishas, Kathleen I.
    Sharma, Sunil
    Lessnick, Stephen L.
    CANCER RESEARCH, 2018, 78 (19)
  • [6] The histone demethylase LSD1/KDM1A as therapeutic target in AML
    Berg, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 272 - +
  • [7] Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy
    Romo-Morales, Antonio
    Aladowicz, Ewa
    Blagg, Julian
    Gatz, Susanne A.
    Shipley, Janet M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (09)
  • [8] KDM1A and mTOR inhibition is a novel therapeutic combination for the treatment of endometrial cancer
    Kost, Edward R.
    Prabhakar, Pitta V.
    Sareddy, Gangadhara
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E27 - E27
  • [9] Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
    Jiang, Qu
    Stachelscheid, Johanna
    Bloehdorn, Johannes
    Pacholewska, Alicja
    Stilgenbauer, Stephan
    Hallek, Michael
    Schweiger, Michal R.
    Vasyutina, Elena
    Herling, Marco
    LEUKEMIA & LYMPHOMA, 2023, 64 : S5 - S6
  • [10] Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML
    Lokken, Alyson A.
    Zeleznik-Le, Nancy J.
    CANCER CELL, 2012, 21 (04) : 451 - 453